Market Overview

UPDATE: H.C. Wainwright & Co. Initiates Coverage on Seattle Genetics on Good Potential for Adcetris

Related SGEN
5 Health Care Stocks Hurting From The Affordable Care Act
Bank Of America Q3 Small & Mid-Cap Biotech Preview

In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on Seattle Genetics (NASDAQ: SGEN) with a Buy rating and $65.00 price target.

In the report, H.C. Wainwright & Co. noted, “We believe that Adcetris, anti-CD30-targeted antibody drug conjugate (ADC), already approved for the treatment of refractory Hodgkin's lymphoma and anaplastic large cell lymphoma, could show further robust activity allowing it to move into new cancer indications and earlier lines of therapy. While Street expectations for SGEN are high, we also believe there could be attractive upside based on prospects for Adcetris, other ADCs, and the technology platform.”

Seattle Genetics closed on Friday at $51.78.

Latest Ratings for SGEN

DateFirmActionFromTo
Oct 2014Cantor FitzgeraldUpgradesSellHold
Sep 2014Bank of AmericaDowngradesUnderperform
Jul 2014UBSUpgradesNeutralBuy

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings

Posted-In: Andrew S. Fein H.C. Wainwright & Co.Analyst Color Initiation Analyst Ratings

 

Related Articles (SGEN)

Around the Web, We're Loving...

Get Benzinga's Newsletters